Design Therapeutics, Inc. (DSGN)
NASDAQ: DSGN · Real-Time Price · USD
11.78
+0.15 (1.29%)
Jul 24, 2026, 4:00 PM EDT - Market closed

Design Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Income
-78.76-79.47-62.38-78.19-67.59-35.83
Net Income
-69.71-69.79-49.59-66.86-63.31-35.53
Earnings Per Share
-1.20-1.22-0.88-1.19-1.14-0.77
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
222.82219.85245.48281.8330.39384.06
Total Debt
2.20.651.532.333.053.14
Net Cash (Debt)
220.63219.2243.94279.46327.34380.92
Net Cash Growth
-3.38%-10.14%-12.71%-14.63%-14.07%955.44%
Net Cash Per Share
3.773.824.314.995.888.29

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-54-54.36-43.11-58.56-51.32-29.38
Capital Expenditures
-0.12-0.19-0.34-0.26-0.92-1.54
Free Cash Flow
-54.12-54.55-43.45-58.82-52.24-30.92
Free Cash Flow Growth
------